NDRG2 and central nervous system cancer: A number of studies using various techniques have shown that epigenetic silencing of the NDRG2 promoter has been found in the majority of primary tumors, and different cancer cell lines and other tumor tissues such as glioma (46.3 - 62%), primary gastric (54%) and colorectal carcinoma (64.28%) cancers [8–11].